Abstract

1343P Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call